用于治疗类风湿性关节炎的氢溴酸吡非尼酮

Peficitinib hydrobromide to treat rheumatoid arthritis.

作者信息

Gutiérrez-Ureña S R, Amaya-Cabrera E L, Uribe-Martínez J F, Ventura-Valenzuela M E, Rosal-Arteaga C, Martínez-Bonilla G E, González-Díaz V, Almengor-Montenegro O, Cerpa-Cruz S

机构信息

Staff, Rheumatology Department, Hospital Civil de Guadalajara FAA, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.

Fellow, Rheumatology Department, Hospital Civil de Guadalajara FAA, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.

出版信息

Drugs Today (Barc). 2020 Aug;56(8):505-514. doi: 10.1358/dot.2020.56.8.3123469.

DOI:10.1358/dot.2020.56.8.3123469

PMID:33025946

Abstract

Peficitinib hydrobromide is a small Janus kinase inhibitor (JAK1, JAK2, JAK3 and TYK2) molecule for the treatment of rheumatoid arthritis (RA). Phase II and phase III clinical trials and extension studies with different doses have been conducted to assess the drug's efficacy and safety with substantially improved outcomes observed in RA. This JAK inhibitor oral drug demonstrated clinical response as once-daily monotherapy in patients with moderate to severe RA, also in combination with methotrexate (MTX), who had an inadequate response to MTX. The findings from studies of this new JAK inhibitor have shown that, both in monotherapy as well as in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), it has efficacy, safety and tolerability in RA patients.

摘要

氢溴酸培非替尼是一种用于治疗类风湿性关节炎（RA）的小型 Janus 激酶抑制剂（JAK1、JAK2、JAK3 和 TYK2）分子。已开展了不同剂量的 II 期和 III 期临床试验及扩展研究，以评估该药物的疗效和安全性，在类风湿性关节炎患者中观察到了显著改善的结果。这种 JAK 抑制剂口服药物在中度至重度类风湿性关节炎患者中作为每日一次单药治疗显示出临床反应，在对甲氨蝶呤（MTX）反应不足的患者中与甲氨蝶呤联合使用时也显示出临床反应。这种新型 JAK 抑制剂的研究结果表明，无论是单药治疗还是与传统合成抗风湿药物（csDMARDs）联合使用，它在类风湿性关节炎患者中都具有疗效、安全性和耐受性。